VolitionRx Nu.Q NETs Assay Selected for French Sepsis Detection Study
VolitionRx Limited's Nu.Q® NETs H3.1 assay has been selected for the DETECSEPS study in France for early sepsis detection. Supported by €6.3 million in French government funding, the assay will be the sole biomarker used alongside the NEWS2 diagnostic test. Results are expected in the future.
VolitionRx Limited has announced the inclusion of its Nu.Q® NETs H3.1 assay in the DETECSEPS real-world evaluation study for early detection of sepsis in France. The DETECSEPS Consortium, supported by approximately €6.3 million in French government funding as part of the France 2030 plan, will utilize the Nu.Q® H3.1 assay as the sole biomarker in the study. The assay is designed to be used alongside the NEWS2 diagnostic test and can be processed using the Immunodiagnostic Systems (IDS) i10® automated analyzer. Results from the study have not yet been presented and are expected in the future. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VolitionRX Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN39349) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
